deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02303951

Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC (NEO-VC)

Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC

Sponsor: University Hospital Tuebingen

Conditions Malignant Melanoma
Interventions Atezolizumab Cobimetinib Vemurafenib
Updated 9 times since 2017 Last updated: Jan 29, 2021 Started: Jan 22, 2015 Primary completion: May 14, 2020 Completion: May 14, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The main reason for the early termination is the low recruitment rate.

Other terminated trials from University Hospital Tuebingen

See all terminations from University Hospital Tuebingen

Other Malignant Melanoma trials with similar outcome

Browse all Malignant Melanoma trials

Listed as NCT02303951, this PHASE2 trial focuses on Malignant Melanoma and remains terminated or withdrawn. Sponsored by University Hospital Tuebingen, it has been updated 9 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Nov 2017 · 10 months · monthly snapshotRecruiting~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshotRecruiting~Jun 2018 – ~May 2019 · 11 months · monthly snapshotRecruiting~May 2019 – ~Dec 2019 · 7 months · monthly snapshotActive Not Recruiting~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotRecruiting~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotRecruiting~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Mar 2021 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  5. Dec 2019 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

▶ Show 4 earlier versions

  1. May 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jun 2018 — May 2019 [monthly]

    Recruiting PHASE2

  3. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  4. Jan 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University Hospital Tuebingen
Data source: University Hospital Tuebingen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations